The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

This month’s Enterprise Connect AI show provided attendees with a look at vertical use cases, end user adoptions – and lessons on how to deploy AI in your own enterprise.

Truist Financial analyst Nicole Germino assigned a Buy rating to the stock today. The company’s shares closed yesterday at $13.00.

Detailed price information for Vivos Therapeutics Inc (VVOS-Q) from The Globe and Mail including charting and trades.

We reached out to VCs to nominate prominent founders in the industry who are committed to bringing potentially life-changing ...

Discover visionary biotech entrepreneurs, nominated by VCs, who are revolutionizing the industry with innovative, ...

Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach ...

SAVANNAH, Georgia — There’s no medical treatment for Charcot-Marie-Tooth (CMT) disease, a debilitating neurologic disorder ...

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of ...

Wedbush has recently initiated Perspective Therapeutics Inc (CATX) stock to Outperform rating, as announced on October 1, 2024, according to Finviz. Earlier, on September 25, 2024 ...

Jasper Therapeutics has reported complete responses in 10 of the 12 chronic hives patients who received the high dose of its ...

Cancer drug developer gets much-needed funds, plus Clarity launches cancer diagnosis trial and LTR delivers ED spray trial ...